Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

High adherence to 5-alpha reductase inhibitor therapy lowers risk of surgery for BPH

31 Jul 2020

Treatment with 5-alpha reductase inhibitor is associated with a reduced risk of surgical intervention in men with benign prostatic hyperplasia (BPH), a recent study has shown. Patients also show high medication adherence outside of clinical trials.

In addition, 5-alpha reductase inhibitor therapy exhibits a modest clinical benefit and appears to be more feasible for older men with BPH than previously reported.

Medication adherence among 3,107 men initiating 5-alpha reductase inhibitor therapy for BPH and filling at least two prescriptions was high (74.9 percent) during the first year. Those with low adherence had 29-percent higher risks of undergoing surgical intervention (95 percent confidence interval [CI], 1.02–1.59; p=0.036) after adjusting for age, BPH severity, presence of haematuria, bladder stones, and type of 5-alpha reductase inhibitors.

Other risk factors for surgical intervention included the presence of bladder stones (hazard ratio [HR], 1.70, 95 percent CI, 1.02–2.86; p=0.04) and use of finasteride vs dutasteride (HR, 1.41, 95 percent CI, 1.01–1.98; p=0.05).

In this study, the investigators identified men initiating a 5-alpha reductase inhibitor for benign prostatic hyperplasia with more than one medication dispensation using healthcare and pharmacy claims from Partners Healthcare Medicare Accountable Care Organization enrolees (January 2009 to July 2018).

Adherence was defined as proportion of days covered of 80 percent. The investigators used Cox proportional hazards model to examine the primary outcome of treatment failure, defined as any BPH-related surgery.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.